Pieris Pharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de Pieris Pharmaceuticals' es Steve Yoder , nombrado en Dec 2014, tiene una permanencia de 9.5 años. compensación anual total es $1.36M, compuesta por 43% salario y 57% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.006% de las acciones de la empresa, por valor de $727.41. La antigüedad media del equipo directivo y de la junta directiva es de 4.7 años y 6.6 años, respectivamente.
Información clave
Steve Yoder
Chief Executive Officer (CEO)
US$1.4m
Compensación total
| Porcentaje del salario del CEO | 43.0% |
| Permanencia del CEO | 9.6yrs |
| Participación del CEO | 0.006% |
| Permanencia media de la dirección | 4.8yrs |
| Promedio de permanencia en la Junta Directiva | 6.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge
Apr 21
We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Mar 19Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Aug 18Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically
May 15Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge
Apr 17Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?
Dec 31Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications
Aug 10Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M
Aug 04Pieris: Early Stage Developer Of Novel Asset Class
Jan 09We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Dec 15Progress At Pieris Pharmaceuticals
Oct 27Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts
Aug 05We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 19Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates
May 22Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
May 19Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week
Apr 01Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like
Mar 08We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Feb 01How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 28
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?
Dec 02Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$1m | US$585k | -US$25m |
| Sep 30 2023 | n/a | n/a | -US$28m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$2m | US$565k | -US$33m |
| Sep 30 2022 | n/a | n/a | -US$35m |
| Jun 30 2022 | n/a | n/a | -US$42m |
| Mar 31 2022 | n/a | n/a | -US$47m |
| Dec 31 2021 | US$2m | US$548k | -US$46m |
| Sep 30 2021 | n/a | n/a | -US$51m |
| Jun 30 2021 | n/a | n/a | -US$48m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$2m | US$535k | -US$37m |
| Sep 30 2020 | n/a | n/a | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$15m |
| Mar 31 2020 | n/a | n/a | -US$22m |
| Dec 31 2019 | US$2m | US$515k | -US$28m |
| Sep 30 2019 | n/a | n/a | -US$36m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$28m |
| Dec 31 2018 | US$3m | US$500k | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$8m |
| Mar 31 2018 | n/a | n/a | -US$18m |
| Dec 31 2017 | US$1m | US$450k | -US$18m |
Compensación vs. Mercado: La compensación total de Steve($USD1.36M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD673.68K).
Compensación vs. Ingresos: La compensación de Steve ha sido consistente con los resultados de la empresa en el último año.
CEO
Steve Yoder (48 yo)
9.6yrs
Permanencia
US$1,358,952
Compensación
Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 9.6yrs | US$1.36m | 0.0057% $ 735.7 | |
| Senior VP | 4.8yrs | US$729.04k | 0.018% $ 2.4k | |
| Senior VP & Chief Development Officer | no data | US$705.45k | 0.0044% $ 568.6 | |
| Executive Director of Investor Relations | no data | sin datos | sin datos | |
| Chief Supply Chain Officer | 4.8yrs | sin datos | sin datos | |
| VP and Head of Alliance Management & Early Project Leadership | 1.5yrs | sin datos | sin datos |
4.8yrs
Permanencia media
48yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de PIRS se considera experimentado (4.7 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 9.6yrs | US$1.36m | 0.0057% $ 735.7 | |
| Independent Chairman | 7.2yrs | US$94.09k | 0.019% $ 2.5k | |
| Independent Director | 9.6yrs | US$52.09k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$72.58k | 0.019% $ 2.5k | |
| Independent Director | 5.8yrs | US$65.08k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$53.09k | 0% $ 0 | |
| Independent Director | 6.3yrs | US$52.09k | 0% $ 0 | |
| Independent Director | 5yrs | US$52.09k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Clinical & Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Clinical & Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Clinical & Scientific Advisory Board | no data | sin datos | sin datos |
6.7yrs
Permanencia media
61.5yo
Promedio de edad
Junta con experiencia: La junta directiva de PIRS se considera experimentada (6.6 años de antigüedad promedio).